CL2009001595A1 - Forma amorfa y cristalina de (2s,3r,4r,5s,6r)-2-(4-cloro-3-(4-etoxibenzil)fenil)-6-(metiltio)tetrahidro-2h-pirano-3,4,5-triol anhidro; composicion farmaceutica que comprende la forma cristalina, util para reducir la glucosa sanguinea, recuperar la sensibilidad a la insulina, tratar la diabetes tipo 2. obesidad. - Google Patents
Forma amorfa y cristalina de (2s,3r,4r,5s,6r)-2-(4-cloro-3-(4-etoxibenzil)fenil)-6-(metiltio)tetrahidro-2h-pirano-3,4,5-triol anhidro; composicion farmaceutica que comprende la forma cristalina, util para reducir la glucosa sanguinea, recuperar la sensibilidad a la insulina, tratar la diabetes tipo 2. obesidad.Info
- Publication number
- CL2009001595A1 CL2009001595A1 CL2009001595A CL2009001595A CL2009001595A1 CL 2009001595 A1 CL2009001595 A1 CL 2009001595A1 CL 2009001595 A CL2009001595 A CL 2009001595A CL 2009001595 A CL2009001595 A CL 2009001595A CL 2009001595 A1 CL2009001595 A1 CL 2009001595A1
- Authority
- CL
- Chile
- Prior art keywords
- crystalline form
- ethoxybenzyl
- triol
- pyran
- methylthio
- Prior art date
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title abstract 3
- 239000008103 glucose Substances 0.000 title abstract 3
- -1 4-chloro-3- (4-ethoxybenzyl) phenyl Chemical group 0.000 title abstract 2
- 206010022489 Insulin Resistance Diseases 0.000 title abstract 2
- 239000008280 blood Substances 0.000 title abstract 2
- 210000004369 blood Anatomy 0.000 title abstract 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 title abstract 2
- 208000008589 Obesity Diseases 0.000 title 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000029142 excretion Effects 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/08—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium or tellurium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Saccharide Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8142308P | 2008-07-17 | 2008-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2009001595A1 true CL2009001595A1 (es) | 2010-07-19 |
Family
ID=41137707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2009001595A CL2009001595A1 (es) | 2008-07-17 | 2009-07-15 | Forma amorfa y cristalina de (2s,3r,4r,5s,6r)-2-(4-cloro-3-(4-etoxibenzil)fenil)-6-(metiltio)tetrahidro-2h-pirano-3,4,5-triol anhidro; composicion farmaceutica que comprende la forma cristalina, util para reducir la glucosa sanguinea, recuperar la sensibilidad a la insulina, tratar la diabetes tipo 2. obesidad. |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US8217156B2 (OSRAM) |
| EP (1) | EP2332947B1 (OSRAM) |
| JP (2) | JP2011528366A (OSRAM) |
| KR (2) | KR101707246B1 (OSRAM) |
| CN (2) | CN102112483A (OSRAM) |
| AR (1) | AR072807A1 (OSRAM) |
| AU (1) | AU2009270973B2 (OSRAM) |
| BR (1) | BRPI0916191A2 (OSRAM) |
| CA (1) | CA2730931A1 (OSRAM) |
| CL (1) | CL2009001595A1 (OSRAM) |
| CO (1) | CO6351797A2 (OSRAM) |
| DK (1) | DK2332947T3 (OSRAM) |
| ES (1) | ES2656357T3 (OSRAM) |
| HK (1) | HK1243713A1 (OSRAM) |
| HU (1) | HUE035400T2 (OSRAM) |
| IL (1) | IL210269A (OSRAM) |
| MX (1) | MX2011000503A (OSRAM) |
| NO (1) | NO2332947T3 (OSRAM) |
| NZ (1) | NZ590184A (OSRAM) |
| PE (1) | PE20100260A1 (OSRAM) |
| PL (1) | PL2332947T3 (OSRAM) |
| PT (1) | PT2332947T (OSRAM) |
| RU (1) | RU2505543C2 (OSRAM) |
| SG (1) | SG185317A1 (OSRAM) |
| TW (1) | TWI472521B (OSRAM) |
| UA (1) | UA106048C2 (OSRAM) |
| UY (1) | UY31992A (OSRAM) |
| WO (1) | WO2010009197A1 (OSRAM) |
| ZA (1) | ZA201100175B (OSRAM) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI499414B (zh) | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法 |
| PT2183263E (pt) | 2007-07-26 | 2012-01-11 | Lexicon Pharmaceuticals Inc | Processos e compostos úteis na preparação de inibidores do co-transportador 2 de glucose e sódio |
| AR072511A1 (es) | 2008-07-15 | 2010-09-01 | Theracos Inc | Derivados deuterados de bencilbenceno y metodos de uso. composicion farmaceutica. |
| TWI472521B (zh) | 2008-07-17 | 2015-02-11 | Lexicon Pharmaceuticals Inc | （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法 |
| TWI562775B (en) * | 2010-03-02 | 2016-12-21 | Lexicon Pharmaceuticals Inc | Methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| CN102453026A (zh) | 2010-10-27 | 2012-05-16 | 上海艾力斯医药科技有限公司 | C-芳基葡糖苷衍生物、制备方法及其应用 |
| TWI631963B (zh) * | 2011-01-05 | 2018-08-11 | 雷西肯製藥股份有限公司 | 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| DK2925735T3 (da) | 2012-11-20 | 2019-06-17 | Lexicon Pharmaceuticals Inc | Inhibitorer for natriumglucose-cotransporter 1 |
| EP3057970A1 (en) | 2013-10-18 | 2016-08-24 | Medivation Technologies, Inc. | Heterocyclic compounds and methods of use |
| US20160272645A1 (en) | 2013-10-18 | 2016-09-22 | Medivation Technologies, Inc. | Heterocyclic Compounds and Methods of Use |
| US10617704B2 (en) | 2015-07-30 | 2020-04-14 | Microbial Chemistry Research Foundation | Effective aminoglycoside antibiotic for multidrug-resistant bacteria |
| EP3466958B1 (en) * | 2016-05-25 | 2020-04-29 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | New crystal forms of sodium-glucose co-transporter inhibitor, processes for preparation and use thereof |
| WO2018067805A1 (en) | 2016-10-06 | 2018-04-12 | Teva Pharmaceutical Industries Ltd. | Solid state forms of sotagliflozin |
| EP3528800A1 (en) | 2016-10-19 | 2019-08-28 | Boehringer Ingelheim International GmbH | Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof |
| CN111989103A (zh) | 2018-04-17 | 2020-11-24 | 勃林格殷格翰国际有限公司 | 药物组合物、其治疗方法和用途 |
| CN110818722B (zh) * | 2018-08-14 | 2022-12-02 | 苏州鹏旭医药科技有限公司 | 三种化合物及其制备方法和在合成索格列净中的用途 |
| CA3100035A1 (en) | 2018-08-27 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Use of raman spectroscopy in downstream purification |
| CA3113037A1 (en) * | 2018-09-26 | 2020-04-02 | Lexicon Pharmaceuticals, Inc. | Crystalline forms of n-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oopropan-2-yl)-4-(4-(2-methyl-5-(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl)phenl)butanamide and methods of their synthesis |
| MY206745A (en) | 2018-10-29 | 2025-01-04 | Boehringer Ingelheim Int | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof |
| JP7425793B2 (ja) | 2018-10-29 | 2024-01-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピリジニルスルホンアミド誘導体、医薬組成物およびそれらの使用 |
| CN109824687B (zh) * | 2019-03-26 | 2022-03-22 | 上海凌凯医药科技有限公司 | 呋喃木糖衍生物的新合成方法 |
| EP3957634A4 (en) * | 2019-07-05 | 2022-08-31 | Shangdong Danhong Pharmaceutical Co., Ltd. | CRYSTALLINE FORM OF SGLT INHIBITOR AND ITS APPLICATION |
| EP3771718A1 (en) * | 2019-08-01 | 2021-02-03 | Lexicon Pharmaceuticals, Inc. | Process for preparing the crystalline form ii of sotagliflozin |
| EP3771480A1 (en) | 2019-08-01 | 2021-02-03 | Lexicon Pharmaceuticals, Inc. | Continuous process for preparing the crystalline form ii of sotagliflozin |
| US20240100013A1 (en) | 2021-01-04 | 2024-03-28 | Lexicon Pharmaceuticals, Inc. | Sotagliflozin for improving left atrial function |
| WO2022155303A1 (en) | 2021-01-14 | 2022-07-21 | Lexicon Pharmaceuticals, Inc. | Sotagliflozin for treating or preventing cardiovascular diseases |
| CN113880701A (zh) * | 2021-10-10 | 2022-01-04 | 浙江司太立制药股份有限公司 | 一种抗糖尿病药物中间体及其制备方法 |
| WO2025072413A1 (en) | 2023-09-28 | 2025-04-03 | Lexicon Pharmaceuticals, Inc. | Methods of treating type 1 diabetes and kidney disease |
| WO2025076165A1 (en) | 2023-10-06 | 2025-04-10 | Lexicon Pharmaceuticals, Inc. | Methods of reducing the risk of cardiovascular events in patients with left ventricular hypertrophy |
| PL446852A1 (pl) * | 2023-11-27 | 2025-06-02 | Politechnika Rzeszowska im. Ignacego Łukasiewicza | Układ doprowadzający wodę do pralki |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3870699A (en) * | 1973-03-06 | 1975-03-11 | Upjohn Co | Lincomycin analogs |
| SK9742002A3 (en) * | 2000-01-07 | 2003-02-04 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| WO2006018150A1 (de) | 2004-08-11 | 2006-02-23 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| DE602006009772D1 (de) | 2005-02-23 | 2009-11-26 | Boehringer Ingelheim Int | Glucopyranosylsubstituierte ((hetero)arylethynyl-benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose-cotransporters typ 2 (sglt2) |
| CN1820858A (zh) * | 2006-03-10 | 2006-08-23 | 广西中医学院制药厂 | 多相物料喷雾方法及装置 |
| TWI499414B (zh) * | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法 |
| WO2008109591A1 (en) * | 2007-03-08 | 2008-09-12 | Lexicon Pharmaceuticals, Inc. | Phlorizin analogs as inhibitors of sodium glucose co-transporter 2 |
| PT2183263E (pt) * | 2007-07-26 | 2012-01-11 | Lexicon Pharmaceuticals Inc | Processos e compostos úteis na preparação de inibidores do co-transportador 2 de glucose e sódio |
| TWI472521B (zh) | 2008-07-17 | 2015-02-11 | Lexicon Pharmaceuticals Inc | （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法 |
-
2009
- 2009-07-01 TW TW98122274A patent/TWI472521B/zh active
- 2009-07-15 US US12/503,225 patent/US8217156B2/en active Active
- 2009-07-15 JP JP2011518868A patent/JP2011528366A/ja active Pending
- 2009-07-15 AU AU2009270973A patent/AU2009270973B2/en active Active
- 2009-07-15 CN CN2009801279245A patent/CN102112483A/zh active Pending
- 2009-07-15 BR BRPI0916191A patent/BRPI0916191A2/pt active IP Right Grant
- 2009-07-15 KR KR1020117001024A patent/KR101707246B1/ko active Active
- 2009-07-15 SG SG2012077681A patent/SG185317A1/en unknown
- 2009-07-15 RU RU2011105797/04A patent/RU2505543C2/ru active
- 2009-07-15 PT PT111551008T patent/PT2332947T/pt unknown
- 2009-07-15 WO PCT/US2009/050636 patent/WO2010009197A1/en not_active Ceased
- 2009-07-15 HU HUE11155100A patent/HUE035400T2/en unknown
- 2009-07-15 MX MX2011000503A patent/MX2011000503A/es active IP Right Grant
- 2009-07-15 CN CN201710477527.7A patent/CN107629097A/zh not_active Withdrawn
- 2009-07-15 NO NO11155100A patent/NO2332947T3/no unknown
- 2009-07-15 DK DK11155100.8T patent/DK2332947T3/da active
- 2009-07-15 PE PE2009000944A patent/PE20100260A1/es not_active Application Discontinuation
- 2009-07-15 CA CA2730931A patent/CA2730931A1/en not_active Abandoned
- 2009-07-15 EP EP11155100.8A patent/EP2332947B1/en active Active
- 2009-07-15 AR ARP090102685A patent/AR072807A1/es unknown
- 2009-07-15 UA UAA201101832A patent/UA106048C2/uk unknown
- 2009-07-15 ES ES11155100.8T patent/ES2656357T3/es active Active
- 2009-07-15 CL CL2009001595A patent/CL2009001595A1/es unknown
- 2009-07-15 KR KR1020177001061A patent/KR20170010069A/ko not_active Ceased
- 2009-07-15 PL PL11155100T patent/PL2332947T3/pl unknown
- 2009-07-15 NZ NZ590184A patent/NZ590184A/xx unknown
- 2009-07-16 UY UY0001031992A patent/UY31992A/es not_active Application Discontinuation
-
2010
- 2010-12-26 IL IL210269A patent/IL210269A/en active IP Right Grant
-
2011
- 2011-01-06 ZA ZA2011/00175A patent/ZA201100175B/en unknown
- 2011-02-09 CO CO11014849A patent/CO6351797A2/es not_active Application Discontinuation
-
2012
- 2012-06-22 US US13/530,645 patent/US9067962B2/en active Active
-
2015
- 2015-09-30 JP JP2015193990A patent/JP6283337B2/ja active Active
-
2018
- 2018-03-02 HK HK18103068.1A patent/HK1243713A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2009001595A1 (es) | Forma amorfa y cristalina de (2s,3r,4r,5s,6r)-2-(4-cloro-3-(4-etoxibenzil)fenil)-6-(metiltio)tetrahidro-2h-pirano-3,4,5-triol anhidro; composicion farmaceutica que comprende la forma cristalina, util para reducir la glucosa sanguinea, recuperar la sensibilidad a la insulina, tratar la diabetes tipo 2. obesidad. | |
| CL2012000991A1 (es) | Compuestos derivados de glicosidos, moduladores de sglt; composicion farmaceutica; y su uso en el sindrome metabolico para tratar enfermedades como diabetes, resistencia a la insulina, disminucion en la tolerancia a la glucosa, entre otras. | |
| HUE035947T2 (hu) | A (2S,3R,4R,5S,6R)-2-(4-klór-3-benzilfenil)-6-(hidroximetil)tetrahidro-2H-pirán-3,4,5-triol származékainak felhasználása a diabétesz kezelésében | |
| EA201391651A1 (ru) | Сокристаллы l-пролина и лимонной кислоты (2s,3r,4r,5s,6r)-2-(3-((5-(4-фторфенил)тиофен-2-ил)метил)-4-метилфенил)-6-(гидроксиметил)тетрагидро-2h-пиран-3,4,5-триол | |
| BRPI0917196B8 (pt) | forma cristalina de um composto sendo complexo de (2s,3r,4r,5s,6r)- 2- (4- cloro- 3- (4- (2- ciclopropoxietóxi) benzil)fenil)- 6- (hidroximetil) tetraidro- 2h- piran- 3,4,5- triol, bis(l-prolina) | |
| WO2012165914A3 (en) | Novel diphenylmethane derivatives as sglt2 inhibitors | |
| AR084781A1 (es) | Composiciones que comprenden y metodos que utilizan inhibidores de los cotransportadores de sodio-glucosa 1 y 2 | |
| CL2008003153A1 (es) | Compuestos espiro condensados, agonistas de gpr40: composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en la preparacion de medicamentos para el tratamiento de la diabetes, hiperglicemia, alteracion de tolerancia a la glucosa en ayuna, entre otras. | |
| WO2011159067A3 (en) | Thiazole derivatives as sglt2 inhibitors and pharmaceutical composition comprising same | |
| NZ605570A (en) | Crystalline form of benzylbenzene sglt2 inhibitor | |
| CL2009000967A1 (es) | Compuesto 4-ciclobutil-n-((2s,5r)-5-hidroxi-2-adamantil)-2-morfolin-4-ilpiridin-5-carboxamida, inhibidor de la enzima 11betahsd1; composicion farmaceutica que lo comprende; y su uso en un procedimiento de tratamiento profilactico o terapeutico de un animal de sangre caliente. | |
| CL2011001757A1 (es) | Uso de una composicion farmaceutica que comprende un inhibidor de sglt2 (1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofuran-3-iloxi)-bencil]-benceno, para mejorar el control glucemico. | |
| BRPI0517701A8 (pt) | métodos de tratamento de diabetes mellitus | |
| PE20110288A1 (es) | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol | |
| BR112012021771A2 (pt) | métodos de uso de inibidores de contransportadores de sódio-glicose 1 e 2. | |
| CL2008002076A1 (es) | Compuestos derivados de ariloxazoles sustituidos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar diabetes, sindrome metabolico, dislipidemias, entre otras enfermedades. | |
| NZ608829A (en) | Pharmaceutical composition comprising an sglt2-inhibitor, methods for treating and uses thereof | |
| PE20091063A1 (es) | FORMA CRISTALINA DE 1-CLORO-4-(ß-D-GLUCOPIRANOS-1-IL)-2-[4-((S)-TETRAHIDROFURAN-3-ILOXI)-BENCIL]-BENCENO Y PROCEDIMIENTO PARA SU PREPARACION | |
| EP1932530A4 (en) | MEANS FOR IMPROVING COLLAGEN PRODUCTION AND ITS USE | |
| CL2007003487A1 (es) | Forma cristalina del hemihidrato de 1-(b-d-glucopiranosil)-4-metil-3-[5-(4-fluorofenil)-2-tienilmetil]benceno, inhibidor del transportador de glucosa sodio-dependiente; proceso de preparacion; composicion farmaceutica, util para el tratamiento de dia | |
| EA201070698A1 (ru) | Твердые формы 3-(6-(1-(2,2-дифторбензо[d][1,3]-диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты | |
| CL2013000768A1 (es) | Composicion farmaceutica que comprende un compuesto derivado de (6s)-6-(2-hidroxi-2-metilpropil)-6-fenil-3-{(1s)-1-[4-(2-oxo-1,2-dihidropiridin-4-il)fenil]etil}-1,3-oxazin-2-ona y un segundo agente terapéutico; y su uso para prevenir o retrasar un trastorno asociado a diabetes mellitus 2 o tolerancia alterada a la glucosa. | |
| CL2008000593A1 (es) | Uso de compuestos derivados de heterociclos sustituidos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad aterosclerotica de las arterias entre otras enfermedades. | |
| CL2004000800A1 (es) | Compuestos derivados de acidos carboxilicos, sustituidos por heterociclos, composicion farmaceutica, util como modulador del receptor activado proliferador de peroxisomas (ppar-y) para tratar diabetes mellitus no insulina dependiente, sindrome de ova | |
| BRPI0518889A2 (pt) | plantas de cana-de-aÇécar com um conteédo de carboidrato de armazenamento aumentado |